Cortés, J. E., & Krämer, A. (2018). Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: An open-label, multicentre, single-arm, phase 2 trial. The lancet. Oncology, 19(7), . https://doi.org/10.1016/S1470-2045(18)30240-7
Chicago-Zitierstil (17. Ausg.)Cortés, Jorge Eduardo, und Alwin Krämer. "Quizartinib, an FLT3 Inhibitor, as Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukaemia: An Open-label, Multicentre, Single-arm, Phase 2 Trial." The Lancet. Oncology 19, no. 7 (2018). https://doi.org/10.1016/S1470-2045(18)30240-7.
MLA-Zitierstil (9. Ausg.)Cortés, Jorge Eduardo, und Alwin Krämer. "Quizartinib, an FLT3 Inhibitor, as Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukaemia: An Open-label, Multicentre, Single-arm, Phase 2 Trial." The Lancet. Oncology, vol. 19, no. 7, 2018, https://doi.org/10.1016/S1470-2045(18)30240-7.